(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 December 2011 (01.12.2011)

PCT

(10) International Publication Number
WO 2011/147810 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 9/00* (2006.01)
A61K 31/437 (2006.01) *A61P 15/00* (2006.01)

(21) International Application Number:
PCT/EP2011/058433

(22) International Filing Date:
24 May 2011 (24.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10 2010 021 637.2 26 May 2010 (26.05.2010) DE
10170413.8 22 July 2010 (22.07.2010) EP

(71) Applicant *(for all designated States except US)*: **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HIRTH-DIETRICH, Claudia** [DE/DE]; Stockmannsmühle 127, 42115 Wuppertal (DE). **SANDNER, Peter** [DE/DE]; Julius-Lucas-Weg 59, 42113 Wuppertal (DE). **STASCH, Johannes-Peter** [DE/DE]; Alfred-Nobel-Str.109, 42651 Solingen (DE). **KNORR, Andreas** [DE/DE]; Trillser Graben 10, 40699 Erkrath (DE). **VON DEGENFELD, Georges** [FR/DE]; Friedrich-Weskott-Str. 10, 51373 Leverkusen (DE). **HAHN, Michael** [DE/DE]; Rietherbach 42D, 40764 Langenfeld (DE). **FOLLMANN, Markus** [DE/DE]; Ringstr. 61, 42489 Wülfrath (DE).

(74) Common Representative: **BAYER PHARMA AKTIENGESELLSCHAFT**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/147810 A1

(54) Title: THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).

(57) Abstract: The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.